Overall Survival Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With HR+/HER2– Metastatic Breast Cancer

Name: Overall Survival Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With HR+/HER2– Metastatic Breast Cancer
Uploaded: 2022-10-18T13:00:00.000Z
Description: Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.

October 18, 2022

Hope S. Rugo, MD

Video

Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.